Hepatitis Be Antigen
| Label Mnemonic: | HBEAG |
| Epic code: | LAB3297 |
| Downtime form: | A-1a Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Chemistry
6240 RCP
356-3527
6240 RCP
356-3527
Specimen(s):
Plasma
Collection Medium:
 |
| Plasma Separator Tube 4.5 mL |
Alternate
Collection Media:
Call laboratory for additional acceptable specimen collection containers.
Minimum:
3 mL whole blood from light green top tube or TWO
Microtainer® devices for pediatric patients
Rejection Criteria:
Heat-inactivated, grossly hemolyzed, or lipemic specimens. Specimens
containing particulate material, or collected in citrate-based
anticoagulant.
Testing Schedule:
24 hrs/day, 7 days a week, including holidays.
Turn Around
Time:
1 hour (upon receipt in laboratory)
Reference Range:
See Interpretive Data
Interpretive Data:
A negative result of <0.90 indicates that Hepatitis Be antigens were
not detected in the sample. A negative test result does not exclude
the possibility of exposure to or infection with HBV.
A positive result of >1.10 indicates presumptive evidence of hepatitis B virus infection. Hepatitis Be antigens were detected in the sample which suggests either on-going or previous HBV infection.
A positive result of >1.10 indicates presumptive evidence of hepatitis B virus infection. Hepatitis Be antigens were detected in the sample which suggests either on-going or previous HBV infection.
Comments:
This assay may be significantly impacted by high-dose biotin (>5 mg
dose) taken within previous 12 hours. High concentrations of biotin
may lead to falsely decreased results. These concentrations may be
found in patients taking over-the-counter supplements with biotin
content much higher than nutritional requirements for biotin.
Specimens should not be collected until at least 12 hours after the
last dose.
Order this test only when specimen is repeatedly reactive for Hepatitis B Surface Antigen.
Assay changed to Roche Elecsys HBeAg on 10/03/2017.
Order this test only when specimen is repeatedly reactive for Hepatitis B Surface Antigen.
Assay changed to Roche Elecsys HBeAg on 10/03/2017.
Test
Limitations:
Assay is unaffected by icterus (<25 mg/dL), hemolysis (Hb <1600
mg/dL), lipemia (triglycerides <1500 mg/dL) and total protein < 12
g/dL.
For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination, and other findings. A reactive HBeAg result does not exclude co- infection by another hepatitis virus. False positive results due to non-specific reactivity cannot be ruled out with this assay. In rare cases, interference due to extremely high titers of antibodies to immunological components, streptavidin and ruthenium can occur. A non- reactive test result does not exclude the possibility of exposure to HBV. Negative HBeAg results may occur during early infection due to delayed seroconversion. False negative results may occur due to antigen levels below the detection limit of this assay or if the patient's antigen does not react with the antibody used in this test.
For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination, and other findings. A reactive HBeAg result does not exclude co- infection by another hepatitis virus. False positive results due to non-specific reactivity cannot be ruled out with this assay. In rare cases, interference due to extremely high titers of antibodies to immunological components, streptavidin and ruthenium can occur. A non- reactive test result does not exclude the possibility of exposure to HBV. Negative HBeAg results may occur during early infection due to delayed seroconversion. False negative results may occur due to antigen levels below the detection limit of this assay or if the patient's antigen does not react with the antibody used in this test.
Methodology:
Electrochemiluminescence Immunoassay
CPT Code:
87350
See Additional Information:
Biotin Interference with Immunoassays
Biotin Interference with Immunoassays